journal article·2026-03Open access

Decoding pH‐Driven Phase Transition of Lipid Nanoparticles

Marius F.W. Trollmann, Rainer A. Böckmann

Small· Volume 22· Issue 14

Abstract

ABSTRACT The functionality of lipid nanoparticles (LNPs) as delivery systems in mRNA‐based therapeutics is intricately linked to the protonation behavior of their aminolipid components. This study employs large‐scale constant‐pH molecular dynamics (CpHMD) simulations to decode the environment‐dependent of aminolipids in the Comirnaty lipid formulation, providing a detailed view of their pH‐dependent structural dynamics. Our results reveal a significant shift in the apparent of the aminolipid ALC‐0315, from an intrinsic value of 9.3 in water to 4.9 within the LNP environment. This shift arises from the interplay between lipid reorganization and local electrostatic interactions, resulting in distinct protonation states across the LNP core and surface. At low pH, protonated aminolipids dominate the LNP surface, promoting efficient mRNA encapsulation, whereas at neutral pH, deprotonated aminolipids migrate to the hydrophobic core, driving structural stabilization. Notably, the localized of aminolipids varies significantly with their position, decreasing from near‐surface regions (7 to 8) to the hydrophobic core (4). These findings elucidate the molecular mechanisms underpinning LNP phase transitions and highlight the key role of shifts for the design of aminolipids and for optimizing LNP compositions for enhanced therapeutic delivery. This study bridges experimental observations with molecular‐level insights, advancing the rational development of next‐generation lipid‐based nanocarriers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Computational Biology Department of Biology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany

Erlangen National High‐Performance Computing Center (NHR@FAU) Erlangen Germany

FAU Research Center New Bioactive Compounds (FAU NeW) Erlangen Germany

FAU Profile Center Immunomedicine (FAU I‐MED) Erlangen Germany

References (80)

Show source-provided references
1. 10.1038/s41573-024-00977-610.1038/s41573-024-00977-6 ↗
2. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
3. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
4. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
5. 10.1016/S1473-3099(21)00677-010.1016/S1473-3099(21)00677-0 ↗
6. 10.1126/scitranslmed.adl272010.1126/scitranslmed.adl2720 ↗
7. A Novel Lipid Nanoparticle (NBF‐006) Encapsulating Glutathione S‐Transferase P (GSTP) siRNA for the Treatment of KRAS‐Driven Non‐Small Cell Lung Cancer10.1158/1538-7445.AM2018-5917 ↗
8. 10.1038/s41541-022-00577-810.1038/s41541-022-00577-8 ↗
9. 10.1038/s41541-023-00679-x10.1038/s41541-023-00679-x ↗
10. 10.1016/j.biopha.2023.11506510.1016/j.biopha.2023.115065 ↗
11. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
12. 10.1038/s42003-021-02441-210.1038/s42003-021-02441-2 ↗
13. 10.1016/S0006-3495(01)76202-910.1016/S0006-3495(01)76202-9 ↗
14. 10.1002/smtd.20170037510.1002/smtd.201700375 ↗
15. 10.1016/S0005-2736(00)00343-610.1016/S0005-2736(00)00343-6 ↗
16. 10.3389/fphar.2020.59817510.3389/fphar.2020.598175 ↗
17. 10.1038/mtna.2013.6610.1038/mtna.2013.66 ↗
18. 10.1039/C9NR09347H10.1039/C9NR09347H ↗
19. 10.1016/j.bpj.2022.08.03710.1016/j.bpj.2022.08.037 ↗
20. 10.1016/j.jconrel.2025.11387910.1016/j.jconrel.2025.113879 ↗
21. 10.1016/j.omtm.2025.10158510.1016/j.omtm.2025.101585 ↗
22. 10.1021/acs.molpharmaceut.4c0042610.1021/acs.molpharmaceut.4c00426 ↗
23. M. J.Hope B.Mui P. J. C.Lin et al. “Lipid Nanoparticle Formulations ”World Patent WO‐2018081480‐A1(May 2018).
24. 10.1083/jcb.20211013710.1083/jcb.202110137 ↗
25. 10.1016/j.jconrel.2005.06.01410.1016/j.jconrel.2005.06.014 ↗
26. 10.1021/la104590k10.1021/la104590k ↗
27. 10.1002/anie.20230497710.1002/anie.202304977 ↗
28. 10.1038/sj.gt.330150610.1038/sj.gt.3301506 ↗
29. 10.1038/nbt.160210.1038/nbt.1602 ↗
30. 10.1073/pnas.172054211510.1073/pnas.1720542115 ↗
31. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
32. 10.1073/pnas.231049112010.1073/pnas.2310491120 ↗
33. 10.1021/acsnano.2c1190410.1021/acsnano.2c11904 ↗
34. 10.1073/pnas.231170012010.1073/pnas.2311700120 ↗
35. 10.1021/acsnano.4c0261010.1021/acsnano.4c02610 ↗
36. 10.1039/C9NR02297J10.1039/C9NR02297J ↗
37. 10.1021/acs.jcim.1c0077010.1021/acs.jcim.1c00770 ↗
38. 10.1021/acs.jpclett.1c0310910.1021/acs.jpclett.1c03109 ↗
39. 10.1063/5.017255210.1063/5.0172552 ↗
40. Mechanistic Insights into Interactions between Ionizable Lipid Nanodroplets and Biomembranes
41. 10.1021/jp303267y10.1021/jp303267y ↗
42. 10.1021/acs.jpcb.5c0498010.1021/acs.jpcb.5c04980 ↗
43. 10.1021/acs.jpcb.2c0767110.1021/acs.jpcb.2c07671 ↗
44. L. R.Kjølbye M.Valério M.Paloncýová et al. “Martini 3 Building Blocks for Lipid Nanoparticle Design ”Journal of Chemical Theory and Computation(2025) Article acs.jctc.5c01207.10.26434/chemrxiv-2024-bf4n8-v2 ↗
45. 10.1016/j.omtm.2025.10159610.1016/j.omtm.2025.101596 ↗
46. 10.1021/ct200061r10.1021/ct200061r ↗
47. 10.1021/acs.jctc.2c0051610.1021/acs.jctc.2c00516 ↗
48. 10.1073/pnas.242299512210.1073/pnas.2422995122 ↗
49. 10.1073/pnas.240455512110.1073/pnas.2404555121 ↗
50. Schrödinger LLC. “The PyMOL Molecular Graphics System Version 3.1 ” (2024) https://github.com/schrodinger/pymol‐open‐source(accessed November 2025).
51. 10.1016/S0005-2736(98)00260-010.1016/S0005-2736(98)00260-0 ↗
52. 10.1063/1.142136210.1063/1.1421362 ↗
53. 10.1063/5.004944810.1063/5.0049448 ↗
54. 10.1016/j.omtm.2025.10157810.1016/j.omtm.2025.101578 ↗
55. 10.1039/D4PM00128A10.1039/D4PM00128A ↗
56. 10.1016/j.ijpharm.2025.12594110.1016/j.ijpharm.2025.125941 ↗
57. 10.1016/j.bios.2024.11606510.1016/j.bios.2024.116065 ↗
58. 10.1038/s41467-023-43892-x10.1038/s41467-023-43892-x ↗
59. 10.1002/smll.20230920010.1002/smll.202309200 ↗
60. 10.1016/j.jconrel.2025.11384810.1016/j.jconrel.2025.113848 ↗
61. K. J.Colston S. C.Monsalve andS. T.Schneebeli “Structure‐Based Modeling of Environment‐Dependent Protonation States across LNP Formulations with Atomistic CpHMD ”Molecular Pharmaceutics(2025) Article acs.molpharmaceut.5c00348.10.26434/chemrxiv-2025-psmd3 ↗
62. 10.1002/anie.20120326310.1002/anie.201203263 ↗
63. 10.1002/jcc.2136710.1002/jcc.21367 ↗
64. SILCSBIO. “CGenFF ” accessed March 25 2024 https://cgenff.com.
65. 10.1021/ci300363c10.1021/ci300363c ↗
66. 10.1021/ci300364910.1021/ci3003649 ↗
67. 10.1021/jp101759q10.1021/jp101759q ↗
68. 10.1021/bi048231w10.1021/bi048231w ↗
69. 10.1021/jp207925m10.1021/jp207925m ↗
70. 10.1021/acs.jcim.3c0131310.1021/acs.jcim.3c01313 ↗
71. 10.1021/acs.jctc.2c0051710.1021/acs.jctc.2c00517 ↗
72. 10.1063/1.240842010.1063/1.2408420 ↗
73. 10.1063/5.002051410.1063/5.0020514 ↗
74. 10.1021/acs.jctc.3c0077710.1021/acs.jctc.3c00777 ↗
75. 10.1063/1.46439710.1063/1.464397 ↗
76. 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H ↗
77. 10.1038/s41586-020-2649-210.1038/s41586-020-2649-2 ↗
78. 10.1002/jcc.2430710.1002/jcc.24307 ↗
79. 10.1002/jcc.2177710.1002/jcc.21777 ↗
80. 10.1002/pol.1947.12002040910.1002/pol.1947.120020409 ↗